These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 16300476

  • 1. Phosphodiesterase-4 as a potential drug target.
    Zhang KY, Ibrahim PN, Gillette S, Bollag G.
    Expert Opin Ther Targets; 2005 Dec; 9(6):1283-305. PubMed ID: 16300476
    [Abstract] [Full Text] [Related]

  • 2. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
    Castro A, Jerez MJ, Gil C, Martinez A.
    Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
    [Abstract] [Full Text] [Related]

  • 3. Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.
    Kroegel C, Foerster M.
    Expert Opin Investig Drugs; 2007 Jan; 16(1):109-24. PubMed ID: 17155857
    [Abstract] [Full Text] [Related]

  • 4. Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.
    Tenor H, Hedbom E, Häuselmann HJ, Schudt C, Hatzelmann A.
    Br J Pharmacol; 2002 Feb; 135(3):609-18. PubMed ID: 11834608
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
    Kapui Z, Bence J, Boronkay E, Mikus E, Urbán Szabó K, Baranyi A, Arányi P.
    Neurobiology (Bp); 1999 Feb; 7(1):71-3. PubMed ID: 10746252
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):110-7. PubMed ID: 16458289
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.
    Wang H, Liu Y, Chen Y, Robinson H, Ke H.
    J Biol Chem; 2005 Sep 02; 280(35):30949-55. PubMed ID: 15994308
    [Abstract] [Full Text] [Related]

  • 17. An Aplysia type 4 phosphodiesterase homolog localizes at the presynaptic terminals of Aplysia neuron and regulates synaptic facilitation.
    Park H, Lee JA, Lee C, Kim MJ, Chang DJ, Kim H, Lee SH, Lee YS, Kaang BK.
    J Neurosci; 2005 Sep 28; 25(39):9037-45. PubMed ID: 16192395
    [Abstract] [Full Text] [Related]

  • 18. Orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H, Ohtani T, Ishida A, Kishikawa K, Obata T, Nakai H, Toda M.
    Bioorg Med Chem Lett; 2004 Mar 08; 14(5):1323-7. PubMed ID: 14980691
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
    Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH, Wharton J.
    Respir Res; 2006 Jan 19; 7(1):9. PubMed ID: 16423283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.